Xiao Ming Zhang, Jiao Feng, Xufan Cai, XU Weilang, Tao Ding, Min He, Yonghui Dong, Xiaoling Xu, Zaiyuan Ye
The Solute Carrier (SLC) family regulates cancer metabolism, supporting proliferation and immune evasion. Key members, such as GLUT1, LAT1, ASCT2, xCT and MCT4, drive metabolic reprogramming and are therapeutic targets. Selective inhibitors like BAY-876 show preclinical efficacy. Combining SLC inhibition with standard therapies may overcome resistance, while personalized strategies and advances in biomarkers and drug delivery are critical for clinical translation.